X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-07-01 | CALC | Calcimedica, Inc. | Stauderman Kenneth A. | Chief Scientific Officer | P - Purchase | $1.85 | +1,000 | 12,944 | +8% | +$1,850 | ||||||
2025-07-02 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Dir | P - Purchase | $0.20 | +60,805 | 1,666,956 | +4% | +$12,161 | ||||||
2025-07-01 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale | $14.65 | -815 | 88,787 | -1% | -$11,940 | ||||||
2025-07-01 | RMTI | Rockwell Medical, Inc. | Chole Timothy | SVP, CCO | S - Sale | $0.82 | -2,868 | 128,167 | -2% | -$2,352 | ||||||
2025-07-01 | RMTI | Rockwell Medical, Inc. | Neri Jesse | SVP, CFO | S - Sale | $0.82 | -886 | 126,614 | -1% | -$727 | ||||||
2025-07-01 | RMTI | Rockwell Medical, Inc. | Strobeck Mark | Pres, CEO | S - Sale | $0.82 | -6,926 | 337,752 | -2% | -$5,679 | ||||||
2025-06-30 | FGEN | Fibrogen Inc | Schoeneck James A | Dir | P - Purchase | $5.07 | +23,567 | 39,666 | +146% | +$119,485 | ||||||
2025-06-30 | XOMA | Xoma Royalty Corp | Sitko Bradley | Chief Investment Officer | P - Purchase | $25.39 | +2,000 | 25,029 | +9% | +$50,780 | ||||||
2025-07-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $13.84 | -9,208 | 100,206 | -8% | -$127,430 | ||||||
2025-06-30 | PMN | Promis Neurosciences Inc. | Gordon Michael S | 10% | S - Sale | $0.00 | -93,223 | 2,123,962 | -4% | -$0 | ||||||
2025-07-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $11.63 | -4,503 | 21,279 | -17% | -$52,379 | ||||||
2025-07-01 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale | $10.05 | -20,000 | 48,317 | -29% | -$200,972 | ||||||
| D | 2025-07-01 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $98.33 | -6,830 | 588,335 | -1% | -$671,612 | |||||
2025-07-01 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $33.55 | -5,000 | 402,274 | -1% | -$167,750 | ||||||
| D | 2025-06-30 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $5.78 | -6,500 | 0 | -100% | -$37,570 | |||||
| D | 2025-06-27 | CRVS | Corvus Pharmaceuticals, Inc. | Orbimed Advisors LLC | Dir, 10% | S - Sale+OE | $4.16 | -1,176,332 | 7,165,006 | -14% | -$4,891,894 | |||||
| D | 2025-06-27 | CRVS | Corvus Pharmaceuticals, Inc. | Thompson Peter A. | Dir, 10% | S - Sale+OE | $4.16 | -1,176,332 | 7,165,006 | -14% | -$4,891,894 | |||||
| M | 2025-06-27 | TRDA | Entrada Therapeutics, Inc. | Parmar Kush | Dir, 10% | S - Sale | $6.93 | -125,000 | 4,283,379 | -3% | -$866,633 | |||||
| M | 2025-06-27 | TRDA | Entrada Therapeutics, Inc. | 5Am Ventures V, L.P. | 10% | S - Sale | $6.93 | -125,000 | 4,283,379 | -3% | -$866,633 | |||||
| M | 2025-06-27 | JUNS | Jupiter Neurosciences, Inc. | Silva Alison D. | Pres + Chief Business Officer | P - Purchase | $1.03 | +1,800 | 112,027 | +2% | +$1,855 | |||||
| M | 2025-06-27 | JUNS | Jupiter Neurosciences, Inc. | Rosen Christer | CEO, COB, 10% | P - Purchase | $1.02 | +7,816 | 11,075,292 | 0% | +$7,986 | |||||
2025-06-27 | BBIO | Bridgebio Pharma, Inc. | Viking Global Investors LP | 10% | S - Sale | $44.00 | -3,500,000 | 18,555,375 | -16% | -$154,000,000 | ||||||
2025-06-27 | SION | Sionna Therapeutics, Inc. | Tpg Gp A, LLC | 10% | P - Purchase | $15.84 | +60,000 | 6,744,962 | +1% | +$950,400 | ||||||
2025-06-30 | AKBA | Akebia Therapeutics, Inc. | Ostrowski Erik | SVP, CFO, CBO, Treasurer | S - Sale | $3.67 | -41,314 | 503,586 | -8% | -$151,622 | ||||||
2025-06-30 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $2.46 | +4,115 | 29,715 | +16% | +$10,123 | ||||||
2025-06-27 | QURE | Uniqure N.V. | Abi-Saab Walid | Chief Medical Officer | S - Sale | $13.92 | -1,466 | 150,437 | -1% | -$20,407 | ||||||
2025-06-27 | SPRY | Ars Pharmaceuticals, Inc. | Flynn James E | 10% | S - Sale | $18.46 | -740,149 | 9,774,508 | -7% | -$13,663,151 | ||||||
| D | 2025-06-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $20.91 | -3,250 | 23,000 | -12% | -$67,956 | |||||
| D | 2025-06-30 | CLYM | Climb Bio, Inc. | Brennan Aoife | Pres, CEO | S - Sale+OE | $1.22 | -20,618 | 48,132 | -30% | -$25,154 | |||||
| D | 2025-06-30 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $35.52 | -6,918 | 526,034 | -1% | -$245,727 | |||||
| D | 2025-06-27 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $80.02 | -20,000 | 61,734 | -24% | -$1,600,400 | |||||
2025-06-30 | ALXO | Alx Oncology Holdings Inc | Pinto Shelly | SVP, Finance, CAO | S - Sale | $0.43 | -1,532 | 88,820 | -2% | -$659 | ||||||
2025-06-26 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | S - Sale | $44.05 | -4,707 | 7,863 | -37% | -$207,327 | ||||||
| A | 2021-12-29 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | P - Purchase | $14.24 | +1,752 | 5,981 | +41% | +$24,948 | |||||
| A | 2021-12-28 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | P - Purchase | $12.84 | +2,338 | 4,229 | +124% | +$30,028 | |||||
2025-06-27 | TERN | Terns Pharmaceuticals, Inc. | Gengos Andrew | CFO | P - Purchase | $3.93 | +10,000 | 25,000 | +67% | +$39,283 | ||||||
2025-06-26 | ZVRA | Zevra Therapeutics, Inc. | Thompson Rahsaan | Chief Legal, Compliance | S - Sale | $9.21 | -24,000 | 42,666 | -36% | -$221,004 | ||||||
| D | 2025-06-27 | ACTU | Actuate Therapeutics, Inc. | Bios Equity Cof, LP | Dir, 10% | P - Purchase | $7.00 | +71,428 | 10,196,456 | +1% | +$499,996 | |||||
| D | 2025-06-27 | ACTU | Actuate Therapeutics, Inc. | Kreis Leslie W. | Dir, 10% | P - Purchase | $7.00 | +71,428 | 10,196,456 | +1% | +$499,996 | |||||
| D | 2025-06-27 | ACTU | Actuate Therapeutics, Inc. | Fletcher Aaron G.L. | Dir, 10% | P - Purchase | $7.00 | +71,428 | 10,196,456 | +1% | +$499,996 | |||||
2025-06-27 | IMRX | Immuneering Corp | Schall Thomas J. | Dir | P - Purchase | $3.66 | +9,500 | 52,885 | +22% | +$34,788 | ||||||
2025-06-26 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $1.44 | +4,500 | 997,410 | 0% | +$6,483 | ||||||
| D | 2025-06-26 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $78.71 | -4,000 | 48,034 | -8% | -$314,826 | |||||
| DM | 2025-06-25 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $79.88 | -10,800 | 63,101 | -15% | -$862,705 | |||||
| D | 2025-06-26 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $285.70 | -11,000 | 36,781 | -23% | -$3,142,718 | |||||
2025-06-27 | NATR | Natures Sunshine Products Inc | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | S - Sale | $11.46 | -2,854,607 | 64,167 | -98% | -$32,713,796 | ||||||
| D | 2025-06-26 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale+OE | $36.13 | -5,877 | 39,098 | -13% | -$212,348 | |||||
2025-06-25 | AIMD | Ainos, Inc. | Lee Ting-Chuan | Dir | S - Sale | $0.51 | -2,894 | 1,428,538 | 0% | -$1,476 | ||||||
| M | 2025-06-25 | AIMD | Ainos, Inc. | Tsai Chun-Jung | Dir | S - Sale | $0.50 | -17,000 | 1,384,997 | -1% | -$8,540 | |||||
| D | 2025-06-26 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $36.13 | -23,669 | 514,982 | -4% | -$855,208 | |||||
| D | 2025-06-26 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $36.13 | -2,675 | 21,004 | -11% | -$96,653 | |||||
| D | 2025-06-24 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale+OE | $7.06 | -16,344 | 937,419 | -2% | -$115,366 | |||||
2025-06-24 | KALA | Kala Bio, Inc. | Kharabi Darius | CHIEF BUSINESS OFFICER | S - Sale | $4.01 | -4,511 | 62,566 | -7% | -$18,089 | ||||||
| D | 2025-06-24 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Dir | S - Sale+OE | $7.02 | -13,321 | 73,056 | -15% | -$93,447 | |||||
2025-06-24 | KALA | Kala Bio, Inc. | Reumuth Mary | CFO | S - Sale | $4.01 | -3,631 | 62,100 | -6% | -$14,560 | ||||||
2025-06-24 | KALA | Kala Bio, Inc. | Bazemore Todd | SEE REMARKS | S - Sale | $4.01 | -4,058 | 83,700 | -5% | -$16,273 | ||||||
2025-06-24 | KALA | Kala Bio, Inc. | Brazzell Romulus K | SEE REMARKS | S - Sale | $4.01 | -5,251 | 82,698 | -6% | -$21,057 | ||||||
2025-06-24 | KALA | Kala Bio, Inc. | Iwicki Mark T | Dir | S - Sale | $4.01 | -13,227 | 258,433 | -5% | -$53,040 | ||||||
| M | 2025-06-24 | NAMS | Newamsterdam Pharma Co N.V. | Topper James N | Dir | P - Purchase | $18.38 | +3,780 | 6,827,133 | 0% | +$69,466 | |||||
| D | 2025-06-26 | CALC | Calcimedica, Inc. | Bardin Stephen | CFO | P - Purchase | $1.50 | +2,000 | 43,000 | +5% | +$3,005 | |||||
| D | 2025-06-24 | AGIO | Agios Pharmaceuticals, Inc. | Burns James William | GC | S - Sale+OE | $33.54 | -2,799 | 28,650 | -9% | -$93,878 | |||||
| D | 2025-06-24 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $33.54 | -2,909 | 56,988 | -5% | -$97,568 | |||||
| D | 2025-06-24 | AGIO | Agios Pharmaceuticals, Inc. | Jones Cecilia | CFO | S - Sale+OE | $33.54 | -1,780 | 30,049 | -6% | -$59,701 | |||||
| D | 2025-06-24 | AGIO | Agios Pharmaceuticals, Inc. | Milanova Tsveta | Chief Commercial Officer | S - Sale+OE | $33.54 | -2,770 | 26,122 | -10% | -$92,906 | |||||
| D | 2025-06-24 | AGIO | Agios Pharmaceuticals, Inc. | Goff Brian | CEO | S - Sale+OE | $33.54 | -18,700 | 111,922 | -14% | -$627,198 | |||||
2025-06-24 | BBIO | Bridgebio Pharma, Inc. | McCormick Frank | Dir | S - Sale | $44.23 | -100,000 | 963,254 | -9% | -$4,422,800 | ||||||
2025-06-25 | RZLT | Rezolute, Inc. | Roberts Brian Kenneth | Chief Medical Officer | P - Purchase | $4.38 | +2,500 | 174,228 | +1% | +$10,939 | ||||||
| M | 2025-06-23 | VERA | Vera Therapeutics, Inc. | Enright Patrick G | Dir | P - Purchase | $21.11 | +250,000 | 3,596,593 | +7% | +$5,277,311 | |||||
| D | 2025-06-25 | CNTA | Centessa Pharmaceuticals Plc | Weinhoff Gregory M | Chief Business Officer | S - Sale+OE | $13.86 | -10,000 | 122,279 | -8% | -$138,642 | |||||
| D | 2025-06-24 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $14.02 | -12,000 | 110,886 | -10% | -$168,218 | |||||
| D | 2025-06-24 | CNTA | Centessa Pharmaceuticals Plc | Accardi Mario Alberto | Pres, Orexin Program | S - Sale+OE | $14.00 | -15,000 | 216,485 | -6% | -$210,000 | |||||
2025-06-23 | OKUR | Onkure Therapeutics, Inc. | Saccomano Nicholas A | Pres, CEO | S - Sale | $2.38 | -88 | 3,594 | -2% | -$210 | ||||||
2025-06-23 | OKUR | Onkure Therapeutics, Inc. | Leverone Jason A. | CFO | S - Sale | $2.38 | -303 | 12,906 | -2% | -$722 | ||||||
2025-06-25 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | CEO | P - Purchase | $3.87 | +23,314 | 47,083 | +98% | +$90,230 | ||||||
2025-06-23 | ONC | Beone Medicines Ltd. | Wang Lai | Global Head of R, D | S - Sale | $260.00 | -1,028 | 1,755,494 | 0% | -$267,280 | ||||||
2025-06-23 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $260.00 | -1,363 | 1,244,693 | 0% | -$354,380 | ||||||
2025-06-24 | ONC | Beone Medicines Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale | $265.50 | -2,007 | 10,132,983 | 0% | -$532,867 | ||||||
2025-06-23 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $261.61 | -3,174 | 54,229,075 | 0% | -$830,360 | ||||||
2025-06-23 | AIMD | Ainos, Inc. | Taiwan Carbon Nano Technology Corp | 10% | S - Sale | $0.00 | -29,476 | 5,470,524 | -1% | -$0 | ||||||
2025-06-24 | UTHR | United Therapeutics Corp | Mesa Nilda | Dir | S - Sale | $289.99 | -645 | 4,883 | -12% | -$187,045 | ||||||
| D | 2025-06-24 | UTHR | United Therapeutics Corp | Giltner Richard | Dir | S - Sale+OE | $289.60 | -3,036 | 19,384 | -14% | -$879,214 | |||||
| M | 2025-06-23 | AKTX | Akari Therapeutics Plc | Gaslightwala Abizer | Pres, CEO | P - Purchase | $1.16 | +6,146 | 277,574 | +2% | +$7,120 | |||||
| D | 2025-06-23 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale+OE | $101.78 | -57,765 | 93,536 | -38% | -$5,879,089 | |||||
2025-06-23 | AIMD | Ainos, Inc. | Ase Test, Inc. | 10% | P - Purchase | $0.00 | +29,476 | 58,887 | +100% | +$0 | ||||||
| D | 2025-06-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.45 | -100,000 | 1,462,223 | -6% | -$1,145,000 | |||||
2025-06-23 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale | $114.08 | -500 | 31,903 | -2% | -$57,042 | ||||||
| M | 2025-06-23 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale | $10.49 | -33,500 | 68,317 | -33% | -$351,384 | |||||
2025-06-20 | QURE | Uniqure N.V. | Springhorn Jeremy P. | Dir | S - Sale | $14.45 | -2,112 | 37,694 | -5% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Post Leonard E | Dir | S - Sale | $14.45 | -2,112 | 29,937 | -7% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale | $14.45 | -2,112 | 20,439 | -9% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Jacques Rachelle Suzanne | Dir | S - Sale | $14.45 | -2,112 | 28,346 | -7% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Gut Robert | Dir | S - Sale | $14.45 | -3,336 | 56,879 | -6% | -$48,205 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Balachandran Madhavan | Dir | S - Sale | $14.45 | -2,112 | 37,697 | -5% | -$30,518 | ||||||
2025-06-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $21.40 | -12,500 | 965,188 | -1% | -$267,458 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Meek David D. | Dir | S - Sale | $14.45 | -2,112 | 34,190 | -6% | -$30,518 | ||||||
2025-06-20 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $7.99 | +5,603 | 3,091,127 | 0% | +$44,768 | ||||||
2025-06-20 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $5.13 | -17,808 | 443,839 | -4% | -$91,355 | ||||||
| M | 2025-06-20 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $5.13 | -4,135 | 109,920 | -4% | -$21,202 | |||||
2025-06-20 | AKTX | Akari Therapeutics Plc | Gaslightwala Abizer | Pres, CEO | P - Purchase | $1.20 | +10,000 | 271,428 | +4% | +$12,000 | ||||||
2025-06-24 | ARVN | Arvinas, Inc. | Saik Andrew | CFO | S - Sale | $7.61 | -5,700 | 164,401 | -3% | -$43,377 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |